Clinical Evaluation of SenseGuard to Detect Respiratory Changes During Home Monitoring of Subjects With High Risk of AECOPD.

  • STATUS
    Recruiting
  • End date
    May 11, 2023
  • participants needed
    100
  • sponsor
    NanoVation
Updated on 11 December 2021

Summary

This is an observational, open labeled study. The study aims to evaluate the capability of SenseGuard (SG) non-invasive wearable device, to detect, post-hoc, early respiratory changes due to exacerbation by daily monitoring of subjects with COPD, at home.

Subjects with COPD, that were discharged following hospitalization due to AECOPD are most susceptible to experience another exacerbation during the first 6 months post admission. Hence, subjects that were discharged from the hospital due to AECOPD during the last 3 months are eligible to the study.

Description

During the study subject will be monitored daily for up to 6 months. Subject will perform 2 daily measurements of tidal breathing with SG, for 8 minutes each. Measurements are performed at the same time window every day; in the morning, before any treatment, and in the evening.

Monitoring will be continued during exacerbations and hospitalization if and when occurred.

Subject will complete a weekly online COPD symptoms assessment questionnaire, sent by email or a text massage.

Subject will report the clinical team about any increase of respiratory symptoms that may lead to exacerbation. Subject will get treatment for confirmed exacerbation according to the Standard of Care. Each case of symptoms and/or confirmed exacerbation will be documented in the CRF and reported to NanoVation team within 24 hours from onset. The daily data obtained by SG, prior to the exacerbation, will be analyzed to detect early respiratory change associated with this exacerbation. This information is critical for SG data interpretation and for the development of early alert for AECOPD.

NanoVation team will provide all subjects with the following: training to use SG, technical support in any case of a problem with the device and reminders to use the SG in case of reduced compliance.

Study will include 3 visits:

Visit 1 - Enrolment visit (Day 0): will be conducted during subject hospitalization or at discharge day, or by inviting eligible subjects to this visit (subjects who were hospitalized during the last 3 months due to AECOPD).

Enrolment of eligible subjects by the clinical team will include:

  • Review of medical record and diagnosis.
  • Evaluation of Inclusion/ exclusion criteria.
  • Subject receives explanation about study.
  • Subject signs the Informed Consent form (ICF).
  • Subject performs baseline Spirometry test.
  • Subject fills a baseline COPD symptoms assessment questionnaire (CSAQ).
  • Next visits are scheduled.
  • Subject receives the SG home kit
  • Subject is trained for self-operation of SG measurement.
  • Subject's data is documented in the CRF.

Visit 2- Follow up visit (at 3 months) Subject will have a routine clinical follow up 3 months after discharge and recruitment to the study. During this visit, subject will undergo a routine spirometry breathing test and complete a usability questionnaire evaluating the daily experience with SG measurement. All data will be documented in the CRF.

Visit 3- End of study visit (at 6 months) Subject will have a routine clinical follow up, Subject will undergo a routine spirometry breathing test and will complete a SG usability questionnaire. Subject will return the SG home kit and all data will be documented in the CRF.

Details
Condition chronic obstructive pulmonary disease, chronic obstructive pulmonary disease (copd), COPD, Chronic Obstructive Lung Disease, COPD (Chronic Obstructive Pulmonary Disease)
Treatment SenseGuard Investigational Device
Clinical Study IdentifierNCT05119374
SponsorNanoVation
Last Modified on11 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female, aged 18
Diagnosed with COPD, 30%< FEV1 <80% predicated, or FEV1>80% and FEV1/FVC < 0.7
Discharged from the hospital during the last 3 months due to AECOPD
Provision of signed and dated informed consent form
Speak, read and understand either Hebrew, Arabic or English
Able to understand study requirements and comply with study procedures
Able to operate a tablet for SG measurement

Exclusion Criteria

Suffer from any physical or cognitive impairment that may affect subject's capability to operate the SG device properly
Pregnant woman or nursing mother
Severely ill with less than 12-month life expectancy
Suffering from serious uncontrolled medical conditions that may interfere with study requirements
Participated in another clinical study during the study period, that may interrupt their participation in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note